Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)

Jazz Pharmaceuticals will add dordaviprone, a potential treatment for a rare brain tumor, to its growing oncology pipeline.

-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ): good value for what you're paying.

Medication company Viatris (NASDAQVTRS) will be reporting results tomorrow before market open. Here’s what to expect.

Biopharma company Jazz Pharmaceuticals (NASDAQJAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% year on year to $1.09 billion. On the other hand, the company’s full-year revenue guidance of $4.28 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $6.60 per share was 13.6% above analysts’ consensus estimates.

Biopharma company Jazz Pharmaceuticals (NASDAQJAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for.

JAZZ PHARMACEUTICALS PLC may be an undervalued stock option. NASDAQ:JAZZ retains a strong financial foundation and an attractive price tag.

When you look at JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQJAZZ)—it offers a great deal for the fundamentals it presents.

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQJAZZ)—it offers a great deal for the fundamentals it presents.

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, revealed by Jazz Pharmaceuticals plc (NASDAQJAZZ). New data on Epidiolex is being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California via nine company-sponsored posters.Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals in 2021.

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ) is a compelling option with its solid fundamentals.

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.

Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!

Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a U.S. marketing application in 2025.